REDWOOD CITY, Calif., Sept. 15, 2021 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. RVMD, a clinical-stage precision oncology company focused on developing targeted drugs to inhibit frontier targets that drive and sustain RAS-addicted cancers, today announced that the company will participate in the upcoming 3rd Annual RAS-Targeted Drug Development Summit being held September 21-23, 2021. Steve Kelsey, M.D., president, research and development, will serve as chairperson for one of the conference's scientific tracks and moderate a panel discussion during the virtual event. In addition, Jan Smith, Ph.D., senior vice president, biology and Bob Nichols, Ph.D., project lead for RMC-6291, the company's development-stage KRASG12C(ON) inhibitor, will each deliver a scientific presentation as part of the conference.
Details of Revolution Medicines' participation in the 3rd Annual RAS-Targeted Drug Development Summit are as follows:
Presentations: | |
Title: | Targeting KRASG12C(ON) & Potential Application to Overcoming Drug Resistance in RAS-Addicted Tumors |
Presenter: | Bob Nichols, Ph.D., project lead for RMC-6291 |
Date: | Wednesday, September 22, 2021 |
Time: | 11:55 a.m. Eastern |
Title: | Combination Strategies to Defeat RAS-Addicted Cancers |
Presenter: | Jan Smith, Ph.D., senior vice president, biology |
Date: | Wednesday, September 22, 2021 |
Time: | 2:00 p.m. Eastern |
Panel Discussion: | |
Title: | On the Horizon – Discussing the Post-Approval Landscape for Successful RAS Drugs Beyond AMG510 |
Moderator: | Steve Kelsey, M.D., president, research and development |
Date: | Thursday, September 23, 2021 |
Time: | 4:15 p.m. Eastern |
Scientific Track: | |
Title: | Validating Robust Combination Strategies |
Chairperson: | Steve Kelsey, M.D., president, research and development |
Date/Time: | Wednesday, September 22, 2021; 11:30 a.m. – 5:00 p.m. Eastern Thursday, September 23, 2021; 11:00 a.m. – 12:30 p.m. Eastern |
Additional information on the Digital RAS-Targeted Drug Discovery Summit is available through the conference website at https://ras-drugdevelopment.com/
About Revolution Medicines, Inc.
Revolution Medicines is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit high-value frontier targets in RAS-addicted cancers. The company possesses sophisticated structure-based drug discovery capabilities built upon deep chemical biology and cancer pharmacology know-how and innovative, proprietary technologies that enable the creation of small molecules tailored to unconventional binding sites.
The company's R&D pipeline comprises RAS(ON) Inhibitors designed to suppress diverse oncogenic variants of RAS proteins, and RAS Companion Inhibitors for use in combination treatment strategies. RAS(ON) Inhibitors in development include RMC-6291, RMC-6236, and a pipeline of research compounds targeting additional RAS variants. RAS Companion Inhibitors in development include RMC-4630, RMC-5552, and RMC-5845.
Contacts:
For Investors:
Vida Strategic Partners
Stephanie Diaz
415-675-7401
sdiaz@vidasp.com
For Media:
Vida Strategic Partners
Tim Brons
415-675-7402
tbrons@vidasp.com
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.